IFNG and non-small cell lung carcinoma: In terms of DC-mediated immunotherapy, a phase II clinic trial using exosomes derived from IFN-γ-matured DCs (IFN-γ-DEX) is being conducted in patients with advanced nonsmall-cell lung carcinoma (NSCLC) at 4 months after platinum-based chemotherapy.